Practitioner characteristics and the treatment of children and adolescents with attention deficit hyperactivity disorder

被引:7
|
作者
Mitchell, Philip B. [1 ,2 ]
Levy, Florence [1 ]
Hadzi-Pavlovic, Dusan [1 ,2 ]
Concannon, Patrick E.
Hutchins, Paul [3 ]
Mulcahy, Desmond L. [7 ]
Clarke, Simon D. [4 ]
Salmelainen, Pia A. [5 ]
Warner, Alexandra [6 ]
Hughes, Clifford F. [6 ]
机构
[1] Univ New S Wales, Sch Psychiat, Randwick, NSW, Australia
[2] Black Dog Inst, Randwick, NSW, Australia
[3] Childrens Hosp, Child Dev Unit, Westmead, NSW, Australia
[4] Westmead Hosp, Dept Adolescent Med, Sydney, NSW, Australia
[5] NSW Dept Hlth, Sydney, NSW, Australia
[6] Clin Excellence Commiss, Sydney, NSW, Australia
[7] Orange Base Hosp, Orange, NSW, Australia
关键词
attention deficit hyperactivity disorder; paediatrician; prescribing; psychiatrist; stimulant; MEDICATIONS;
D O I
10.1111/j.1440-1754.2011.02242.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: To investigate whether recent Australian practice conforms to the draft 2009 National Health and Medical Research Council (NHMRC) guidelines on the management of attention deficit hyperactivity disorder. Methods: Data from the 2007 Special Review on Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales (NSW) were examined. Results: Two hundred seven approved stimulant prescribers in NSW responded to a detailed survey on treatment practice (including 121 paediatricians and 67 psychiatrists). Overall, the practice identified in this survey of NSW approved stimulant prescribers was consistent with that recommended in the draft NHMRC guidelines. Paediatricians were more likely to inform families of developmental therapies. Most prescribers (67%) considered stimulants to be the first line of treatment for at least half of their patients. Psychiatrists were more likely to use stimulants as first-line treatments, while those recently qualified were less likely to prescribe. Half of the prescribers were willing to consider prescribing for children 4 years of age and younger. Paediatricians were more likely to consider prescribing to this age group, while those recently qualified were less likely. There were no significant differences in prescribing practice between child and adult psychiatrists. Most prescribers (6797%) routinely monitored patients on stimulants for weight, height, blood pressure and academic progress. Psychiatrists were less likely to review these parameters than paediatricians, with this difference being largely due to adult psychiatrists. Conclusions: There are significant differences in prescribing practice between paediatricians and psychiatrists. These variations may reflect differing training programs and patient populations, and merit close consideration in any review arising from the publication of the recent NHMRC guideline.
引用
收藏
页码:483 / 489
页数:7
相关论文
共 50 条
  • [21] Attention-deficit/hyperactivity disorder in children and adolescents
    Dunn, DW
    Kronenberger, WG
    [J]. NEUROLOGIC CLINICS, 2003, 21 (04) : 933 - +
  • [22] Venlafaxine in children and adolescents with attention deficit hyperactivity disorder
    Mukaddes, NM
    Abali, O
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (01) : 92 - 95
  • [23] Treatment of attention deficit hyperactivity disorder in children
    Kehoe, WA
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1130 - 1134
  • [24] Treatment of attention deficit hyperactivity disorder in children
    van der Oord, Saskia
    Prins, P. J. M.
    Oosterlaan, J.
    Emmelkamp, P. M. G.
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2008, 17 (02) : 73 - 81
  • [25] Practitioner Review: Assessment and treatment of preschool children with attention-deficit/hyperactivity disorder
    Halperin, Jeffrey M.
    Marks, David J.
    [J]. JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2019, 60 (09) : 930 - 943
  • [26] Methylphenidate in the treatment of children and adolescents with bipolar disorder and Attention-Deficit/Hyperactivity disorder
    Findling, Robert L.
    Short, Elizabeth J.
    McNamara, Nora K.
    Demeter, Christine A.
    Stansbrey, Robert J.
    Gracious, Barbara L.
    Whipkey, Resaca
    Manos, Michael J.
    Calabrese, Joseph R.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (11): : 1445 - 1453
  • [27] Treatment adherence and parents' characteristics in children with attention deficit hyperactivity disorder
    Lee, S.
    Seo, H.
    Lim, H.
    Jeong, J.
    Hong, S.
    Han, J.
    Kim, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S426 - S427
  • [28] PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
    Palli, S. R.
    Aparasu, R. R.
    Chen, H.
    Sherer, J. T.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A200 - A200
  • [29] Atomoxetine:: a new treatment for attention deficit/hyperactivity disorder (ADHD) in children and adolescents
    Purper-Ouakil, D
    Fourneret, P
    Wohl, M
    Rénéric, JP
    [J]. ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (03): : 337 - 348
  • [30] Efficacy and safety of atomoxetine in the treatment of attention deficit/hyperactivity disorder in children and adolescents
    Brown, WJ
    Biederman, J
    Spencer, T
    Heiligenstein, J
    Wernicke, J
    Allen, AJ
    Faries, D
    Michelson, D
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S411 - S411